SCHEDULE 13G/A: Sofinnova Capital VIII Discloses 2.7% Passive Stake in Quince Therapeutics

Sofinnova Capital VIII and its affiliates have filed an amended Schedule 13G, reporting a 2.7% beneficial ownership stake in Quince Therapeutics, Inc. as of March 31, 2025.

Summary

• Sofinnova Capital VIII, along with its management company Sofinnova Partners SAS and its investment committee members (Antoine Papiernik, Henrijette Richter, Maina Bhaman, Graziano Seghezzi, Anta Gkelou, and Karl Naegler), collectively reported beneficial ownership of 1,197,711 shares of Quince Therapeutics, Inc. common stock.
• This ownership represents 2.7% of Quince Therapeutics, Inc.'s outstanding common stock.
• The percentage is calculated based on 44,001,643 shares of Quince Therapeutics, Inc. common stock outstanding as of March 13, 2025, as disclosed in the company's Annual Report on Form 10-K filed on March 24, 2025.
• The filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Quince Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing (Schedule 13G/A) disclosing beneficial ownership. It contains no subjective language, financial performance data, or operational updates that would indicate a positive or negative sentiment. It is purely informational.

Positives

• The filing indicates a continued investment by Sofinnova Capital VIII, a notable investment entity, in Quince Therapeutics, Inc.
• The passive nature of the investment, as certified by the filers, suggests no immediate intent to influence or change the control of the issuer, which can provide stability.

Negatives

• The filing does not contain any negative financial or operational information about Quince Therapeutics, Inc. as it is a beneficial ownership disclosure.

Risks

• The document itself does not detail specific risks related to Quince Therapeutics, Inc.'s operations or financial health, as it is a disclosure of beneficial ownership.

Future Outlook

This Schedule 13G/A filing does not contain any forward-looking statements or guidance regarding Quince Therapeutics, Inc.'s future performance or strategic direction.

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor in a publicly traded biotechnology company. Such filings provide transparency into significant ownership stakes, which can be of interest to other investors tracking institutional positions within the biotechnology and pharmaceutical sectors. Sofinnova Capital VIII is a venture capital fund focused on life sciences, and its investment in Quince Therapeutics aligns with typical venture capital investment strategies in the biotech industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive ownership stake by an institutional investor, confirming the investor's continued position in the company.

Key Dates

Keywords

Quince Therapeutics, Sofinnova Capital VIII, Sofinnova Partners SAS, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment, Biotechnology, Pharmaceuticals